The health and budget impact of sodium-glucose co-transporter-2 inhibitors (SGLT2is) in the Netherlands.
Alexander V van SchoonhovenMarcel H SchöttlerErik H SernéPatrick P G SchrömbgesMaarten Jacobus PostmaCornelis BoersmaPublished in: Journal of medical economics (2023)
SGLT2is offer an option to reduce the number of CVD and CKD related events and associated healthcare costs and health losses in the Netherlands. Further research is needed to include the benefits of improved T2DM management options from a broader societal perspective.